Focus: Kymera Therapeutics is a biotech company specializing in targeted protein degradation (TPD) using small molecules, headquartered in Watertown, MA. The company operates in early-stage development across immunology, respiratory, and oncology indications.
Profile data last refreshed Yesterday · AI intelligence enriched 2mo ago
Hot — 24 jobs added in 30d
Net +23 (24 new, 1 removed). Aggressive expansion phase.
Ideal for scientists and clinicians seeking early-stage innovation ownership in an emerging modality, but unsuitable for those prioritizing near-term job security or clinical validation signals.
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Help build intelligence for Kymera Therapeutics
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
Generated by Claude from Kymera Therapeutics's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.
Based on last 4 crawl cycles
Source: USCIS H-1B Employer Data Hub
Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.
Upgrade to Pro — $25/mo